urowebinar: how to manage cvd risk in pca patience during covid 19
Published 3 years ago • 326 plays • Length 1:03:17Download video MP4
Download video MP3
Similar videos
-
58:16
urowebinar: module 3: advances in safety in the treatment of pca
-
10:28
anzup therap study (lu-177 psma-617 vs. cabazitaxel): overall survival after 3 years follow-up
-
11:23
therap study: lu-psma vs. cabazitaxel #asco20 #anzup
-
56:59
parp inhibitors: best practices in advanced prostate cancer care in the community
-
1:28
why pci: why choose pci urology
-
21:55
evidence-based guideline for management of priapism: perspectives from aua/eau guideline panel
-
1:39
challenges in the field of parpi treatment for mcrpc
-
7:39
psmafore phase 3 study
-
5:04
prasugrel and ticagrelor in kidney failure
-
2:26
empiric vs optimal treatment for patients suffering from cutis
-
2:27
pcss- treatment options for urinary control issues
-
16:59
three tailored devices to ease the complex pci procedures - europcr 2024
-
3:35
provider perspectives and clinical outcomes with inpatient telenephrology
-
1:04:24
urowebinar: new treatment options in mcrpc
-
13:57
innovative access solutions for complex pci - europcr 2022
-
45:45
tavi lifetime management: tailoring treatment options to secure future possibilities - europcr 2023
-
16:01
how to refine my #tavi procedure to ensure optimal long-term patient outcomes?
-
2:02
antiplatelet therapy in patients with prior cva [id 39216]